Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer

Sponsor
Women's Hospital School Of Medicine Zhejiang University
Study ID
NCT07369986
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Iparomlimab and Tuvonralimab (QL1706) — DRUG
    Iparomlimab and Tuvonralimab as a strategy to facilitate non-surgical management in women with surgically completely resectable dMMR endometrial cancer.

Study Details

Efficacy evaluate of iparomlimab and tuvonralimab (a PD-1/CTLA-4 bispecific antibody) in patients with surgically resectable dMMR endometrial cancer.

Key Dates

First listed
Jan 27, 2026
Start date
Mar 1, 2026
Status verified
Jan 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Immunotherapy

Primary Outcome Measure

Pathological or clinical complete response rate [ Time Frame: From the time of enrollment until 12 months after the completion of treatment ]

Central Contacts

Find similar trials

Nationwide
Endometrial cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials

Related Studies